The path to routine use of genomic biomarkers in the cancer clinic
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
It has been almost 15 years since the first microarray-based studies creating multigene biomarkers to subtype and predict survival of cancer patients. This Perspective looks at why only a handful of genomic biomarkers have reached clinical application and what advances are needed over the next 15 years to grow this number. I discuss challenges in creating biomarkers and reproducing them at the genomic and computational levels, including the problem of spatio-genomic heterogeneity in an individual cancer. I then outline the challenges in translating newly discovered genome-wide or regional events, like trinucleotide mutation signatures, kataegis, and chromothripsis, into biomarkers, as well as the importance of incorporating prior biological knowledge. Lastly, I outline the practical problems of pharmaco-economics and adoption: Are new biomarkers viewed as economically rational by potential funders? And if they are, how can their results be communicated effectively to patients and their clinicians? Genomic-based diagnostics have immense potential for transforming the management of cancer. The next 15 years will see a surge of research into the topics here that, when combined with a stream of new targeted therapies being developed, will personalize the cancer clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · cited 2×
“…of cancer genomes, such as mutational signatures (Alexandrov et al. 2013a,b), focal genomic abnormalities like kataegis and chromothripsis (Stephens et al. 2011), robust estimates of the distribution and number of driver genes (Lawrence et al. 2014), and classification of many tumor types…”
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299 · cited 1×
“…like the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have been sequencing hundreds of tumors of different subtypes to try to create catalogs of those that are recurrent in any given cancer type (The Cancer Genome Atlas Research Network 2008; Hudson et al. 2010).”
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126 · cited 1×
“For example, several studies of microarray processing techniques have yielded discordant results (Shedden et al. 2005; Shi et al. 2005, 2006, 2010; Canales et al. 2006; Zhu et al. 2010).”
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“…of kidney (Gerlinger et al. 2012, 2014; Gulati et al. 2014), prostate (Boutros et al. 2015; Cooper et al. 2015; Gundem et al. 2015), breast (Shah et al. 2012; Eirew et al. 2015), lung (de Bruin et al. 2014; Zhang et al. 2014), ovarian (Bashashati et al. 2013; Anglesio et al. 2015), and…”
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
MAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889 · cited 1×
“For example, several studies of microarray processing techniques have yielded discordant results (Shedden et al. 2005; Shi et al. 2005, 2006, 2010; Canales et al. 2006; Zhu et al. 2010).”
Vaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Yuan, Y., Failmezger, H., Rueda, O. M., Ali, H. R., Gräf, S., Chin, S.-F., Schwarz, R. F., Curtis, C., Dunning, M. J., Bardwell, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004330 · Cited by 426
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342 · cited 2×
“Nevertheless, there is already evidence that global mutation burden can be prognostic in multiple tumor types (Lalonde et al. 2014; Vollan et al. 2015) and that trinucleotide signatures and mutation burden may be predictive of response to targeted therapies (Rizvi et al. 2015), making reproducible…”
Self-citation
Research works printed but not linked: 67
- 2014, Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nat Commun, 5, 4006, 10.1038/ncomms5006 · DOI · Paper page
- 10.1038/nature12477 · DOI · Paper page
- 10.1016/j.celrep.2012.12.008 · DOI · Paper page
- 10.1002/path.4516 · DOI · Paper page
- 10.1016/j.cell.2013.03.021 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-0357 · DOI
- 10.1002/path.4230 · DOI · Paper page
- 10.1038/nature09744 · DOI · Paper page
- 10.1073/pnas.0809444106 · DOI · Paper page
- 10.1038/ng.2932 · DOI
- 10.1186/s13059-014-0462-7 · DOI · Paper page
- 10.1038/ng.3315 · DOI · Paper page
- 10.1101/013177 · DOI
- 10.1038/nbt1236 · DOI · Paper page
- 10.1038/nature11252 · DOI · Paper page
- 10.1038/nature11412 · DOI · Paper page
- 10.1038/nature14129 · DOI · Paper page
- 10.1038/nature07385 · DOI · Paper page
- 10.1038/nmeth.3094 · DOI
- 10.1038/ng.3221 · DOI · Paper page
- 10.1038/nmeth.3440 · DOI · Paper page
- 10.1038/nature10983 · DOI · Paper page
- 10.1038/nmeth.2375 · DOI · Paper page
- 10.1186/s13059-015-0602-8 · DOI · Paper page
- 10.1038/nature12108 · DOI · Paper page
- 10.1038/nature13952 · DOI · Paper page
- 10.1038/nmeth.3407 · DOI · Paper page
- 10.1038/nm1764 · DOI · Paper page
- 10.1186/1471-2105-15-170 · DOI
- 10.1056/NEJMoa1113205 · DOI · Paper page
- 10.1038/ng.2891 · DOI · Paper page
- 10.1038/nmeth.2562 · DOI · Paper page
- 10.1186/1471-2105-15-78 · DOI
- 10.1016/j.eururo.2014.06.053 · DOI · Paper page
- 10.1038/nature14347 · DOI · Paper page
- 10.1101/gr.180281.114 · DOI · Paper page
- 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- 10.1016/j.cell.2011.02.013 · DOI · Paper page
- 10.1056/NEJMoa0804525 · DOI · Paper page
- 10.1016/S0140-6736(11)61941-7 · DOI · Paper page
- 10.1002/path.4047 · DOI · Paper page
- 10.1038/nature12213 · DOI · Paper page
- 10.1038/nature12912 · DOI · Paper page
- 10.1038/ng.3168 · DOI · Paper page
- 10.1200/JCO.2010.30.6373 · DOI
- 10.1126/scitranslmed.3006112 · DOI · Paper page
- 10.1200/JCO.2008.17.9762 · DOI · Paper page
- 10.1093/bioinformatics/btu651 · DOI
- 10.1126/science.aaa1348 · DOI · Paper page
- 10.1038/nmeth.2883 · DOI · Paper page
- 10.1038/nature08489 · DOI · Paper page
- 10.1186/1471-2105-6-26 · DOI
- 2005, Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential, BMC Bioinformatics, 6, pS12, 10.1186/1471-2105-6-S2-S12 · DOI · Paper page
- 10.1371/journal.pone.0028320 · DOI
- 10.1186/gm385 · DOI
- 10.1158/1078-0432.CCR-14-1749 · DOI
- 10.1016/j.celrep.2014.08.073 · DOI
- 10.1002/ijc.27817 · DOI
- 10.1038/nm.3559 · DOI · Paper page
- 10.1038/415530a · DOI · Paper page
- 10.1371/journal.pcbi.1002240 · DOI · Paper page
- 10.1016/j.molonc.2014.07.019 · DOI
- 10.1186/gb-2010-11-5-r53 · DOI · Paper page
- 10.1016/j.cell.2013.04.010 · DOI · Paper page
- 10.1038/nbt.2940 · DOI · Paper page
- 10.1038/ng.2760 · DOI · Paper page
- 10.1186/1471-2105-11-285 · DOI
Cited by
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Experimental design and quantitative analysis of microbial community multiomics
Mallick, H., Ma, S., Franzosa, E. A., Vatanen, T., Morgan, X. C., & Huttenhower, C. (2017) · Genome Biology · doi:10.1186/s13059-017-1359-z · Cited by 192
Identification of human gene research articles with wrongly identified nucleotide sequences
Park, Y., West, R. A., Pathmendra, P., Favier, B., Stoeger, T., Capes-Davis, A., Cabanac, G., Labbé, C., & Byrne, J. A. (2022) · Life Science Alliance · doi:10.26508/lsa.202101203 · Cited by 37
“genome was reported (3, 4), a series of increasingly rapid technological advances has permitted the routine sequencing of human genomes at scale (1, 2), and the increasing application of genomics to inform clinical care (1, 2, 5).”
Byrne, J. A., Grima, N., Capes-Davis, A., & Labbé, C. (2019) · Biomarker Insights · doi:10.1177/1177271919829162 · Cited by 34
“In summary, the current landscape that combines (1) many thousands of under-studied Figure 2.”
Background
Metadata
- Authors
- Boutros, P. C.
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-10
- Volume
- 25
- Issue
- 10
- Pages
- 1508-1513
- ISSN
- 1088-9051 (ISSN-L)
- 1549-5469
- OpenAlex
- W2172874849
- Cited by
- 40
- References
- 12
- Type
- posted content
- Language
- en
- Open access
- bronze
- Funders
- Ontario Institute for Cancer Research
- Prostate Cancer Canada
- Movember Foundation (RS2014-01)
- Terry Fox Research Institute
- CIHR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.